Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening Programs

Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening

The communication of an altered Pap smear or positive HPV test has a strong impact on patients on a psychological level. HPV positive women are more likely to have higher level of stress, anxiety, depression and impaired sexual life.

The examiner want to establish this impact through different surveys (DASS-21 (Depression Anxiety Stress Scales); PCL-5 (Posttraumatic Stress Disorder Checklist); DTS (Dyadic Trust Scale), CDDQ (Cervical Dysplasia Distress Questionnaire) and MPI (Match Patient Inventory) from the moment the patient receives the news until after completing treatment for her intraepithelial neoplasia.

Study Overview

• Status: Recruiting
• Conditions: HPV Infection; Papilloma Viral Infection; Physiological Stress

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

Study Locations

• Italy
  • TO
    • Turin, TO, Italy, 10126
      • Recruiting
      • Ospedale Sant'Anna
      • Contact: Mario Preti, MD; Phone Number: 3406175388; Email: mario.preti@unito.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

All the patients accessing our Colposcopy service from Prevenzione Serena program with an altered pap smear or a two-times positive HPV test

Description

Inclusion Criteria:

• patients accessing our Colposcopy service from Prevenzione Serena program with an altered pap smear or a two-times positive HPV test
• patients with biopsy result of HSIL
• ability to fill in surveys via e-mail

Exclusion Criteria:

• previous access in our Colposcopy service
• patients not enrolled in Prevenzione Serena
• pregnant patients
• inability to fill in surveys via email
• partial or total language barrier
• denied consent to participate

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
counselling A; receiving counselling prior to surgery in person
counselling B; receiving counselling prior to surgery via telephone and with a video

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
DASS-21 (Depression Anxiety Stress Scales).	0 Did not apply at all 1 Applied to some degree 2 Applied to a considerable degree 3 Applied very much. I found it hard to wind down; I was aware of dryness of my mouth;I couldn't seem to experience any positive feeling at all I experienced breathing difficulty ; I found it difficult to work up the initiative to do things ;I tended to over-react to situations;I experienced trembling ;I felt that I was using a lot of nervous energy; I was worried about situations in which I might panic; I felt that I had nothing to look forward to; I found myself getting agitated; I found it difficult to relax ; I felt down-hearted and blue ; I was intolerant of anything that kept me from getting on with what I was doing ; I felt I was close to panic ; I was unable to become enthusiastic about anything ; I felt I wasn't worth much as a person ; I felt that I was rather touchy; I was aware of my heart in the absence of physical exertion ; I felt scared without reason; i felt that life was meaningless	3 to 6 months
PCL-5 (Posttraumatic Stress Disorder Checklist);	Not at all 0 A little bit 1 Moderately 2 Quite a bit 3 Extremely 4 Disturbing, unwanted memories of the stressful experience? Repeated dreams of it? Feeling or acting as if it were re-happening? Feeling very upset when reminded of it? Strong physical reactions when reminded? Avoiding memories or thoughts related to the experience? Avoiding external reminders? Trouble remembering important parts of it? Strong negative beliefs about yourself, others, or the world? Blaming yourself or others for the experience or its aftermath? Strong negative feelings like fear, horror, anger, guilt, or shame? Loss of interest in activities you used to enjoy? Feeling distant or cut off from others? Trouble experiencing positive feelings? Irritable behavior, angry outbursts, or acting aggressively? Taking too many risks or doing things that could harm you? Being "superalert"? Feeling easily startled? Difficulty concentrating? Trouble falling asleep?	3 to 6 months
DTS (Dyadic Trust Scale)	Strongly Disagree Disagree Neutral Agree Strongly Agree 1 2 3 4 5 Please rate the extent to which you agree or disagree with each statement: My partner is primarily interested in his/her own welfare. 1 2 3 4 5 There are times when my partner cannot be trusted. 1 2 3 4 5 My partner is perfectly honest and truthful with me. 1 2 3 4 5 I feel that I can trust my partner completely. 1 2 3 4 5 My partner is truly sincere in his/her promises. 1 2 3 4 5 I feel that my partner does not show me enough consideration. 1 2 3 4 5 My partner treats me fairly and justly. 1 2 3 4 5 I feel that my partner can be counted on to help me. 1 2 3 4 5 My partner behaves in a very consistent manner. 1 2 3 4 5 My partner is always honest with me. 1 2 3 4 5 Scoring: To determine the trust level, reverse score the negatively worded items (1, 2, and 6). For these items, change the scoring as follows: 1 becomes 5, 2 becomes 4, 3 stays the same, 4 becomes 2, and 5 becomes 1.	3 to 6 months
CDDQ (Cervical Dysplasia Distress Questionnaire)	Not at all A little bit Moderately Quite a bit Extremely 0 1 2 3 4 Please rate how much you have been distressed by each of the following in the past week, including today: Worrying about the possibility of developing cancer. 0 1 2 3 4 Feeling anxious about future medical procedures. 0 1 2 3 4 Feeling down or depressed about your diagnosis. 0 1 2 3 4 Concerns about the impact of the diagnosis on your sexual relationships. 0 1 2 3 4 Feeling stressed about having to undergo regular follow-up tests. 0 1 2 3 4 Worrying about how others might react to your diagnosis. 0 1 2 3 4 Feeling upset about the uncertainty of your health status. 0 1 2 3 4 Concerns about fertility or future pregnancies. 0 1 2 3 4 Feeling isolated or alone in dealing with your diagnosis. 0 1 2 3 4 Experiencing intrusive thoughts about your condition. 0 1 2 3 4	3 to 6 months
MPI (Match Patient Inventory)	Strongly Disagree 1Disagree2Neutral3Agree 4Strongly Agree5Impossible to Evaluate6 The doctor: Greeted me in a way that made me feel comfortable. Discussed the reason(s) that brought me here today. Encouraged me to express my thoughts about my health problem. Listened carefully to what I had to say. Understood what I had to say. the doctor explained what was done and why. Explained the necessary lab tests Discussed treatment options with me. Gave me all the information I wanted.Checked whether the treatment plan(s) were acceptable to me. Gave explanations regarding any medications, including possible side effects. Encouraged me to ask questions. Answered my questions and concerns. Involved me in decisions as much as I wanted. Discussed the next steps, including any follow-up plans. Made sure I understood everything. Showed interest and concern for me as a person. Spent the right amount of time with me. Overall, I am satisfied with today's visit with the doctor	3 to 6 months

Collaborators and Investigators

• Sponsor: University of Turin, Italy

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2022
• Primary Completion (Estimated): May 1, 2025
• Study Completion (Estimated): July 1, 2025

Study Registration Dates

• First Submitted: June 16, 2023
• First Submitted That Met QC Criteria: July 10, 2024
• First Posted (Actual): July 15, 2024

Study Record Updates

• Last Update Posted (Actual): July 15, 2024
• Last Update Submitted That Met QC Criteria: July 10, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Disease Attributes; DNA Virus Infections; Tumor Virus Infections; Neoplasms, Squamous Cell; Urogenital Diseases; Genital Diseases; Infections; Communicable Diseases; Virus Diseases; Papillomavirus Infections; Papilloma
• Other Study ID Numbers: University of Torino

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No